Athersys (ATHX) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATHX shares.
View ATHX analyst ratings or view top-rated stocks.

1 analysts have issued 12-month target prices for Athersys' shares. Their ATHX share price forecasts range from $5.50 to $5.50. On average, they expect the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 456.6% from the stock's current price.
View analysts price targets for ATHX or view top-rated stocks among Wall Street analysts.

Athersys' stock was trading at $0.84 on January 1st, 2023. Since then, ATHX stock has increased by 17.6% and is now trading at $0.9881.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ATHX earnings forecast.

Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings data on Friday, March, 31st. The biopharmaceutical company reported ($0.83) EPS for the quarter. The biopharmaceutical company had revenue of $0.03 million for the quarter.

Shares of Athersys reverse split before market open on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Athersys' stock is owned by a number of institutional and retail investors. Top institutional investors include Vahanian & Associates Financial Planning Inc. (4.44%), State Street Corp (0.23%), CIBC Asset Management Inc (0.20%), Group One Trading L.P. (0.00%), Simplicity Solutions LLC (0.17%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Daniel A Camardo, Ismail Kola, Ivor Macleod, John J Harrington, John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends.

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATHX stock can currently be purchased for approximately $0.99.

Athersys (NASDAQ:ATHX) has a market capitalization of $18.23 million and generates $5.32 million in revenue each year. The biopharmaceutical company earns $-72,530,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

The company employs 104 workers across the globe.

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for the company is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495.